Surrozen - Company Profile

Pioneering targeted regenerative antibodies to repair tissue and restore organ function. This company is developing a new class of therapeutics focused on tissue regeneration. Through selective activation of the Wnt pathway with targeted antibodies, they aim to treat serious diseases characterized by tissue injury. They design tissue-specific antibodies that engage the body’s own biological repair mechanisms, developing a pipeline of first-in-class drug candidates. Their platform promises to overcome limitations of regenerative medicines. Combining Wnt pathway biology understanding with advanced antibody engineering, they design tissue-specific antibodies with the potential to regenerate tissue across various organs and tissues. They are currently focused on Ophthalmology, addressing severe eye diseases. Their uniquely-engineered antibodies selectively modulate the Wnt pathway to repair tissue damage and improve organ function. Their vision is to engage the body’s own biological tissue repair mechanisms with their targeted regenerative antibodies.